JP2003517041A5 - - Google Patents

Download PDF

Info

Publication number
JP2003517041A5
JP2003517041A5 JP2001545542A JP2001545542A JP2003517041A5 JP 2003517041 A5 JP2003517041 A5 JP 2003517041A5 JP 2001545542 A JP2001545542 A JP 2001545542A JP 2001545542 A JP2001545542 A JP 2001545542A JP 2003517041 A5 JP2003517041 A5 JP 2003517041A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
seq
phosphodiester nucleotide
synthetic phosphodiester
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001545542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003517041A (ja
JP4772245B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2000/001467 external-priority patent/WO2001044465A2/en
Publication of JP2003517041A publication Critical patent/JP2003517041A/ja
Publication of JP2003517041A5 publication Critical patent/JP2003517041A5/ja
Application granted granted Critical
Publication of JP4772245B2 publication Critical patent/JP4772245B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001545542A 1999-12-13 2000-12-12 治療上有用な合成オリゴヌクレオチド Expired - Fee Related JP4772245B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17032599P 1999-12-13 1999-12-13
US60/170,325 1999-12-13
US22892500P 2000-08-29 2000-08-29
US60/228,925 2000-08-29
PCT/CA2000/001467 WO2001044465A2 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides

Publications (3)

Publication Number Publication Date
JP2003517041A JP2003517041A (ja) 2003-05-20
JP2003517041A5 true JP2003517041A5 (https=) 2008-02-07
JP4772245B2 JP4772245B2 (ja) 2011-09-14

Family

ID=26865979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001545542A Expired - Fee Related JP4772245B2 (ja) 1999-12-13 2000-12-12 治療上有用な合成オリゴヌクレオチド

Country Status (18)

Country Link
US (2) US7157436B2 (https=)
EP (2) EP1867718B1 (https=)
JP (1) JP4772245B2 (https=)
KR (1) KR100829646B1 (https=)
CN (2) CN100445380C (https=)
AT (2) ATE455851T1 (https=)
AU (1) AU785212B2 (https=)
CA (1) CA2393808A1 (https=)
CZ (1) CZ20022372A3 (https=)
DE (2) DE60036019T2 (https=)
DK (2) DK1867718T3 (https=)
ES (2) ES2340807T3 (https=)
HU (1) HUP0300627A3 (https=)
IL (2) IL150196A0 (https=)
MX (1) MXPA02005842A (https=)
NO (1) NO330508B1 (https=)
PT (1) PT1238070E (https=)
WO (1) WO2001044465A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
JP2002541264A (ja) 1999-04-08 2002-12-03 ユーエイビー・リサーチ・ファウンデーション 冨ｇオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
WO2002018593A2 (en) 2000-08-29 2002-03-07 Bioniche Life Sciences Inc. Modulation of fas and fasl expression
EP1867718B1 (en) * 1999-12-13 2010-01-20 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
DK1417307T3 (da) * 2001-08-17 2009-07-13 Bioniche Life Sciences Inc Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptose
DE60208400T2 (de) * 2001-10-03 2006-07-06 Bioniche Life Sciences Inc., Belleville Therapeutisch verwendbare triethylenglykol-cholesteryl-oligonukleotide
KR101092043B1 (ko) 2002-04-22 2011-12-12 바이오니취 라이프 사이언시즈 인코포레이티드 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
MXPA05012421A (es) * 2003-05-16 2006-02-22 Hybridon Inc Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
US20080009455A9 (en) * 2005-02-24 2008-01-10 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
CA2600440A1 (en) * 2005-03-09 2006-09-21 Baylor College Of Medicine Direct reversal of the suppressive function of cd4+ regulatory t cells via toll-like receptor 8 signaling
US20090087456A1 (en) * 2005-09-07 2009-04-02 James Edward Eyles Adjuvanted vaccine
CN102439149B (zh) * 2009-02-12 2018-01-02 库尔纳公司 通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
WO2011008305A1 (en) * 2009-07-15 2011-01-20 Enzon Pharmaceuticals, Inc. Rna antagonists targeting gli2 for the treatment of leukemia
EP2821504A4 (en) * 2012-02-28 2016-02-17 Univ Tokyo Nat Univ Corp METHOD FOR DETERMINING A DISEASE RELATED TO TDP-43 CONCENTRATION IN CELLS
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
KR20240126870A (ko) 2021-12-22 2024-08-21 캠프4 테라퓨틱스 코포레이션 조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (https=) * 1971-11-19 1975-02-07 Anvar
CA1020460A (en) * 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) * 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DE3723075A1 (de) 1987-07-11 1989-01-19 Boehringer Mannheim Gmbh Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
WO1992014842A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
US6475795B1 (en) * 1991-07-03 2002-11-05 Meditech Research, Ltd. Use of hyaluronan in gene therapy
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
BR9406496A (pt) * 1993-01-29 1996-01-02 Vetrepharm Inc Processo e composição para estimulação do sistema imunológico em um ser humano ou animal
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CN1154702A (zh) * 1994-05-25 1997-07-16 海布里登公司 具有抗巨细胞病毒活性的寡核苷酸
DE69533037T2 (de) * 1994-08-30 2005-05-04 Commonwealth Scientific And Industrial Research Organisation Pflanzentraskriptionsregulator von circovirus
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN181358B (https=) * 1995-02-14 1998-05-30 Bioniche Inc
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
CZ154898A3 (cs) * 1995-11-21 1998-09-16 Icn Pharmaceuticals, Inc. Oligonukleotidy pro inhibici růstu nádorů zprostředkovaných IL-8 a receptorem IL-8
IT1277025B1 (it) 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
EP1011729B1 (en) * 1996-05-20 2008-01-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligonucleotides which specifically bind retroviral nucleocapsid proteins
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
NZ517929A (en) * 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
EP1867718B1 (en) * 1999-12-13 2010-01-20 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
CA2395493C (en) * 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
DE60208400T2 (de) * 2001-10-03 2006-07-06 Bioniche Life Sciences Inc., Belleville Therapeutisch verwendbare triethylenglykol-cholesteryl-oligonukleotide
KR101092043B1 (ko) * 2002-04-22 2011-12-12 바이오니취 라이프 사이언시즈 인코포레이티드 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도

Similar Documents

Publication Publication Date Title
JP2003517041A5 (https=)
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
NZ522326A (en) Adenosine A2A receptor antagonists
HUP0900587A3 (en) Stable salts of 3,3-diphenylpropylamines and preparation thereof
JP2002060340A5 (https=)
JP2002532222A5 (https=)
ZA200404306B (en) 3'-prodrugs of 2'-deoxy-beta-L-nucleosides.
HUP0300527A3 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
JP2002510633A5 (https=)
NZ521879A (en) Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
MXPA03004714A (es) Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion.
AU2002305236A8 (en) Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
HK1052346A1 (zh) 有效用作β-2-肾上腺素受体激动剂以及PDE4-抑制剂的化合物
ZA200105293B (en) Use of growth hormone secretagogues for treatment of physical performance decline.
HUP0103072A3 (en) Use of growth hormone secretagogues
GB2369617B (en) Novel 4,5-dihydroisoxazolylalkyl-piperazine or-piperidine derivatives having selective biological activity at dopamine D3orD4 receptor,and preparation thereof
JP2002522501A5 (https=)
JP2002540769A5 (https=)
HUP0204554A3 (en) Endoparasiticidal composition, preparation and use thereof
CA2353205A1 (en) Agent for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
MXPA03004498A (es) Uso de pirazolo (4,3-d)pirimidinas.
HRP20020989B1 (hr) Enantiomer 1,2-aneliranog kinolina koji inhibira farnezil transferazu
JP2003516751A5 (https=)
AU4742101A (en) Antagonists of gonadotropin releasing hormone